Discrimination of prohibited oral use from authorized inhaled treatment of budesonide in sports

Therapeutic Drug Monitoring

Volumn 35, Issue 1, 2013, Pages 118-128

  Matabosch, Xavier ^a   Pozo, Oscar J ^a   Pérez Mañá, Clara ^b,c   Farré, Magi ^b,c   Marcos, Josep ^a,d   Segura, Jordi ^a,d   Ventura, Rosa ^a,d  

^a HOSPITAL DEL MAR   (Spain)

^b Human Pharmacology and Neurosciences Research Group   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

budesonide; doping; LC MS MS; metabolites; routes of administration

Indexed keywords

16ALPHA HYDROXYPREDNISOLONE; 6ALPHA HYDROXYBUDESONIDE; 6BETA HYDROXYBUDESONIDE; BUDESONIDE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CALIBRATION; CROSSOVER PROCEDURE; DOPING; DRUG ADMINISTRATION ROUTE; DRUG DISCRIMINATION; DRUG URINE LEVEL; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; HUMAN EXPERIMENT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STEREOCHEMISTRY; TANDEM MASS SPECTROMETRY; URINALYSIS;

ADMINISTRATION, INHALATION; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; SENSITIVITY AND SPECIFICITY; SPORTS; TANDEM MASS SPECTROMETRY;

EID: 84872838923     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182787b20     Document Type: Article

References (17)

1. Matabosch X, Pozo OJ, Pérez-Mañá C, et al. Identification of budesonide metabolites in human urine after oral administration. Anal Bioanal Chem. 2012;404:325-340.
2. Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs. 1984;28:485-518.
3. Brogden RN, McTavish D. Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs. 1992;44:375-407.
4. McKeage K, Goa KL. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults. Drugs. 2002;62:2263-2282.
5. The World Anti-Doping Code. The 2012 Prohibited List. International Standard [World Anti-Doping Agency Web site]. Available at: http://www.wada-ama. org/Documents/World-Anti-Doping-Program/WADPProhibited-list/2012/ WADA-Prohibited-List-2012-EN.pdf. Accessed July 9, 2012.
6. Minimum required performance levels for detection of prohibited substances [World Anti-Doping Agency Web site]. Available at: http://www.wada-ama.org/Documents/World-Anti-Doping-Program/WADPIS-Laboratories/ WADA-TD2010MRPLv1.0-Minimum%20Required%20Performance%20Levels-Sept%2001%202010- EN.pdf. Accessed July 9, 2012.
7. Deventer K, Delbeke FT. Validation of a screening method for corticosteroids in doping analysis by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2003;17:2107-2114.
8. Mazzarino M, Turi S, Botre F. A screening method for the detection of synthetic glucocorticosteroids in human urine by liquid chromatographymass spectrometry based on class-characteristic fragmentation pathways. Anal Bioanal Chem. 2008;390:1389-1402.
9. Parr MK, Schanzer W. Detection of the misuse of steroids in doping control. J Steroid Biochem Mol Biol. 2010;121:528-537.
10. Deventer K, Mikulcikova P, Van Hoecke H, et al. Detection of budesonide in human urine after inhalation by liquid chromatography-mass spectrometry. J Pharm Biomed Anal. 2006;42:474-479.
11. 2010 Adverse Analytical Findings and Atypical Findings [World Anti- Doping Agency Web site]. Available at: http://www.wada-ama.org/Documents/ Resources/Statistics/Laboratory-Statistics/WADA-2010-Laboratory-Statistics- Report.pdf. Accessed July 9, 2012.
12. Berges R, Segura J, de la Torre X, et al. Analytical methodology for enantiomers of salbutamol in human urine for application in doping control. J Chromatogr B Biomed Sci Appl. 1999;723:173-184.
13. Ventura R, Segura J, Berges R, et al. Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control. Ther Drug Monit. 2000;22:277-282.
14. Berges R, Segura J, Ventura R, et al. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. Clin Chem. 2000;46:1365-1375.
15. Mareck U, Guddat S, Schwenke A, et al. Determination of salbutamol and salbutamol glucuronide in human urine by means of liquid chromatography- tandem mass spectrometry. Drug Test Anal. 2011;3:820-827.
16. Validation of Analytical Procedures: Text and Methodology. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use. Geneva, Switzerland: ICH-Q2B; 1996.
17. Sweetman SC. Martindale: The Complete Drug Reference. 37th ed. London, United Kingdom: The Pharmaceutical Press; 2011.